Lead Compass Investment
Lead Compass Investment is a venture capital firm based in Seongnam-si, South Korea, that focuses on both international and domestic investments in early-stage biotechnology companies. The firm specializes in identifying and supporting innovative biotech startups, aiming to foster growth and advancement in the sector. By concentrating on early-stage ventures, Lead Compass Investment seeks to capitalize on emerging opportunities within the biotechnology landscape, contributing to the development of cutting-edge solutions in healthcare and related fields.
Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center. Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developing new drugs that overcome resistance of existing therapeutic approaches. Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer.
OxVax Ltd. is a spin-out company from the University of Oxford dedicated to developing an advanced dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's innovative technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a unique subset that presents promising properties for cancer immunotherapy. This approach seeks to provide effective treatment options for patients with intractable cancers, leveraging the potential of dendritic cells to enhance the immune response against tumors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.